Fig. 2: Effects of plateletcrit and the MTHFR 677 TT genotype on folic acid treatment for first stroke prevention. | Signal Transduction and Targeted Therapy

Fig. 2: Effects of plateletcrit and the MTHFR 677 TT genotype on folic acid treatment for first stroke prevention.

From: Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Fig. 2

Among the MTHFR 677 TT genotype population, total homocysteine metabolism dysfunction causes vascular endothelial injury, accelerates platelet aggregation and activation, thus leading to a large consumption of platelets and a decrease in plateletcrit, which ultimately promotes thrombosis and stroke. Folic acid treatment can prevent endothelial damage, reduce total homocysteine levels and the first stroke risk in the TT genotype populations. This figure was created with the aid of Biorender (https://biorender.com/)

Back to article page